Deal Watch, Focus On Asia: Cipla Licenses India Rights To Lilly’s Basalgar
Cipla expands on its in-licensing strategy in India with Lilly’s insulin glargine product, while Aptose signs second agreement with CrystalGenomics to add Chinese rights for leukemia candidate CG-806, and Yakult gains Japanese rights to Verastem's duvelisib.
You may also be interested in...
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
Scrip takes a look at Korean out-licensing deal trends and rankings in 2018, finding biotech-related transactions were dominant.
Amid increasing exports of new drug Acelex and multiple out-licensing agreements for its investigative oncology drugs, the South Korean biotech is raising sizable new funds via stocks and bonds this year to seek new longer term growth engines by bringing in new drug assets, or seeking M&As and alliances, and speeding up progress of its R&D pipeline in global markets.